Spots Global Cancer Trial Database for antineoplastic agents, immunological
Every month we try and update this database with for antineoplastic agents, immunological cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers | NCT04485013 | Cancer | TTX-080 TTX-080 pembrolizumab cetuximab | 18 Years - | Tizona Therapeutics, Inc | |
| Neoadjuvant Sasanlimab With Radiation as an in Situ Vaccine for Cisplatin-ineligible Muscle Invasive Bladder Cancer | NCT05241340 | Urothelial Carc... | Sasanlimab Stereotactic Bo... Radical Cystect... | 18 Years - | The Methodist Hospital Research Institute | |
| A Phase 1 Study of GNR-051 in Subjects With Advanced Malignancies | NCT04544748 | Carcinoma, Non-... Carcinoma, Rena... Melanoma | GNR-051 | 18 Years - | AO GENERIUM | |
| Combination Therapy of HAIC, Surufatinib and Tislelizumab for Unresectable or Metastatic Biliary Tract Cancer | NCT06134193 | Carcinoma Intrahepatic Ch... Gallbladder Can... Surufatinib Angiogenesis In... Tislelizumab Antineoplastic ... Immunotherapy | HAIC Surufatinib Tislelizumab | 18 Years - 75 Years | Wuhan Union Hospital, China | |
| A Phase 1 Study of GNR-051 in Subjects With Advanced Malignancies | NCT04544748 | Carcinoma, Non-... Carcinoma, Rena... Melanoma | GNR-051 | 18 Years - | AO GENERIUM | |
| Hepatic Arterial Infusion of Autologous Tumor Infiltrating Lymphocytes in Patients With Melanoma and Liver Metastases | NCT04812470 | Metastatic Uvea... Metastatic Cuta... | Autologous Tumo... Melphalan Interleukin-2 | 18 Years - | Vastra Gotaland Region | |
| A Study to Evaluate TACE Sequential Tislelizumab as Adjuvant Therapy in Participants With HCC at High Risk of Recurrence After Curative Resection | NCT04981665 | Hepatocellular ... Adjuvant Therap... | Tislelizumab TACE | 18 Years - | Zhejiang University | |
| Neo-DIANA: Neoadjuvant Treatment for EGFR Mutated Patients | NCT04512430 | Non Small Cell ... EGFR Gene Mutat... | Atezolizumab Bevacizumab Carboplatin Pemetrexed | 18 Years - | Fundación GECP | |
| Neoadjuvant Sasanlimab With Radiation as an in Situ Vaccine for Cisplatin-ineligible Muscle Invasive Bladder Cancer | NCT05241340 | Urothelial Carc... | Sasanlimab Stereotactic Bo... Radical Cystect... | 18 Years - | The Methodist Hospital Research Institute | |
| Study of DF6215 in Patients With Advanced Solid Tumors | NCT06108479 | Solid Tumor, Ad... | DF6215 | 18 Years - | Dragonfly Therapeutics | |
| Hepatic Arterial Infusion of Autologous Tumor Infiltrating Lymphocytes in Patients With Melanoma and Liver Metastases | NCT04812470 | Metastatic Uvea... Metastatic Cuta... | Autologous Tumo... Melphalan Interleukin-2 | 18 Years - | Vastra Gotaland Region | |
| Pembrolizumab Plus Chemo in Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma (Eastern Cooperative Thoracic Oncology Projects 2004, ECTOP-2004) | NCT05281003 | Esophageal Squa... | Pembrolizumab Paclitaxel Cisplatin | 18 Years - 75 Years | Fudan University | |
| Pembrolizumab Plus Chemo in Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma (Eastern Cooperative Thoracic Oncology Projects 2004, ECTOP-2004) | NCT05281003 | Esophageal Squa... | Pembrolizumab Paclitaxel Cisplatin | 18 Years - 75 Years | Fudan University | |
| TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers | NCT04485013 | Cancer | TTX-080 TTX-080 pembrolizumab cetuximab | 18 Years - | Tizona Therapeutics, Inc |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
